The development of effective chemotherapy for central nervous system tumors is hampered by the blood-brain barrier and by limited drug diffusion in the brain tissue. BAY 59-8862 is a new taxane analog that was selected and developed for its activity against tumors with a P-glycoprotein-mediated, multidrug-resistant phenotype. Because P-glycoprotein is implicated in limiting the access of drugs to central nervous system tumor targets, the objective of this study was to evaluate the ability of intravenously administered BAY 59-8862 to affect the growth of central nervous system tumors.
|Titolo:||A novel taxane active against an orthotopically growing human glioma xenograft|
|Parole Chiave:||BAY 59-8862; Central nervous system; Human glioma; IDN 5109; Orthotopic xenograft; Paclitaxel; Taxanes|
|Settore Scientifico Disciplinare:||Settore VET/03 - Patologia Generale e Anatomia Patologica Veterinaria|
|Data di pubblicazione:||15-dic-2001|
|Digital Object Identifier (DOI):||10.1002/1097-0142(20011215)92:12<3085::AID-CNCR10150>3.0.CO;2-S|
|Appare nelle tipologie:||01 - Articolo su periodico|